Cardiff Oncology to Participate in Fireside Chat at the Piper Sandler 32nd Annual Healthcare Conference

Rhea-AI Summary

Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotechnology company focused on developing cancer treatments, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference. A pre-recorded fireside chat with the company's management will be available from November 23 to December 3. Additionally, Cardiff Oncology will conduct 1x1 meetings from December 1 to 3, requested exclusively through Piper Sandler. The company's investigational drug, onvansertib, targets multiple cancers, including KRAS-mutated colorectal cancer and castration-resistant prostate cancer.

SAN DIEGO, Nov. 23, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing a drug to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, today announced that the Company will be participating in the upcoming Piper Sandler 32^nd Annual Virtual Healthcare Conference. Beginning today, November 23^rd, a pre-recorded fireside chat with company management will be available for viewing anytime through December 3^rd by accessing the recording library on the Piper Sandler conference site.

Cardiff Oncology will also be participating in 1x1 meetings from December 1^st – 3^rd.  Meetings can be requested exclusively via Piper Sandler.

About Cardiff Oncology, Inc.
Cardiff Oncology (formerly Trovagene, Inc.) is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need.  Our goal is to overcome resistance, improve response to treatment and increase overall survival.  We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics.  Our clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment. We have three ongoing clinical programs that are demonstrating the safety and efficacy of onvansertib: a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin® in KRAS-mutated metastatic colorectal cancer (mCRC); a Phase 2 study of onvansertib in combination with Zytiga® (abiraterone)/prednisone in metastatic castration-resistant prostate cancer (mCRPC); and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia (AML). For more information, please visit https://cardiffoncology.com.  

Cardiff Oncology Contact:
Vicki Kelemen
EVP and Chief Operating Officer
858-952-7652
vkelemen@cardiffoncology.com  

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com 

Media Contact:
Karen O'Shea, Ph.D.
LifeSci Communications
929-469-3860
koshea@lifescicomms.com 

View original content to download multimedia:http://www.prnewswire.com/news-releases/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference-301178519.html

SOURCE Cardiff Oncology, Inc.

FAQ

What is Cardiff Oncology's presentation schedule at Piper Sandler conference?

Cardiff Oncology will host a pre-recorded fireside chat available from November 23 to December 3.

When will Cardiff Oncology hold 1x1 meetings?

Cardiff Oncology will conduct 1x1 meetings from December 1 to December 3.

What is the focus of Cardiff Oncology's research?

Cardiff Oncology is focused on developing treatments for cancers with high medical needs, including KRAS-mutated cancers.

What investigational drug is Cardiff Oncology developing?

Cardiff Oncology is developing onvansertib, a first-in-class Polo-like Kinase 1 (PLK1) inhibitor.

What cancers is onvansertib being evaluated for?

Onvansertib is being evaluated for KRAS-mutated colorectal cancer, castration-resistant prostate cancer, and acute myeloid leukemia.